Brief Title |
Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
|
Official Title |
A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
|
Principal Investigator |
Vokes, Everett
|
Brief Summary |
A study in patients with metastatic or recurrent squamous cell cancer of the head and neck to
evaluate the effectiveness of Nivolumab plus Ipilumumab vs. Nivolumab alone (CheckMate 714)
|
Gender |
All
|
Ages |
18 Years
|
Enrollment |
315
|
Accepts Healthy Volunteers |
No
|
Lead Sponsor |
Bristol-Myers SquibbIndustry
|
Collaborator |
|
Study Design |
|
Study Phase |
Phase 2
|
Study Type |
Interventional
|
Contact Name |
|
Contact Phone |
1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
|
Condition |
Head and Neck Cancer
|